Exploration of Deregulated Long Non-Coding RNAs in Association with Hepatocarcinogenesis and Survival by Shen, Jing et al.






Exploration of Deregulated Long Non-Coding RNAs in
Association with Hepatocarcinogenesis and Survival
Jing Shen 1,2,*, Abby B. Siegel 2,3, Helen Remotti 4, Qiao Wang 1, Yueyue Shen 1,: and
Regina M. Santella 1,2
1 Department of Environmental Health Sciences, Mailman School of Public Health,
Columbia University Medical Center, New York, NY 10032, USA;
E-Mails: qw6@cumc.columbia.edu (Q.W.); Yueyue.Shen@uvm.edu (Y.S.);
rps1@cumc.columbia.edu (R.M.S.)
2 Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York,
NY 10032, USA
3 Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA;
E-Mail: aas54@cumc.columbia.edu
4 Department of Pathology and Cell Biology, Columbia University Medical Center, New York,
NY 10032, USA; E-Mail: her2007@cumc.columbia.edu
: Current address: University of Vermont College of Medicine, Box No. 374, 89 Beaumont Ave.,
Burlington, VT 05405, USA.
* Author to whom correspondence should be addressed; E-Mail: js2182@cumc.columbia.edu;
Tel.: +1-212-305-8158; Fax: +1-212-305-5328.
Academic Editor: Charles H. Lawrie
Received: 15 June 2015 / Accepted: 2 September 2015 / Published: 10 September 2015
Abstract: Long non-coding RNAs (lncRNAs) are larger than 200 nucleotides in length
and pervasively expressed across the genome. An increasing number of studies indicate that
lncRNA transcripts play integral regulatory roles in cellular growth, division, differentiation
and apoptosis. Deregulated lncRNAs have been observed in a variety of human cancers,
including hepatocellular carcinoma (HCC). We determined the expression profiles of
90 lncRNAs for 65 paired HCC tumor and adjacent non-tumor tissues, and 55 lncRNAs
were expressed in over 90% of samples. Eight lncRNAs were significantly down-regulated
in HCC tumor compared to non-tumor tissues (p < 0.05), but no lncRNA achieved statistical
significance after Bonferroni correction for multiple comparisons. Within tumor tissues,
carrying more aberrant lncRNAs (6–7) was associated with a borderline significant reduction
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in survival (HR = 8.5, 95% CI: 1.0–72.5). The predictive accuracy depicted by the
AUC was 0.93 for HCC survival when using seven deregulated lncRNAs (likelihood ratio
test p = 0.001), which was similar to that combining the seven lncRNAs with tumor size
and treatment (AUC = 0.96, sensitivity = 87%, specificity = 87%). These data suggest the
potential association of deregulated lncRNAs with hepatocarcinogenesis and HCC survival.
Keywords: long non-coding RNAs; deregulation; HCC; HBV; survival
1. Introduction
The incidence of hepatocellular carcinoma (HCC) in the United States has tripled over the past
30 years [1–3]. HCC has an extremely poor prognosis if not diagnosed and treated at an early stage.
The average 5-year survival rate is less than 12% [4], and only 3% in advanced disease. Therefore, early
detection of HCC is crucial for successful curative treatment. The aberrant expression of protein-coding
genes play an important role in hepatocarcinogenesis, but these genes only account for 1%–2% of
transcribed RNAs [5–7].
A recent human transcriptome study revealed that a large number of non-coding RNAs (ncRNAs),
including long ncRNA (lncRNA), are abundant in human tissues and crucial regulators of cellular
transcription and translation [5,8,9]. LncRNA, larger than 200 nucleotides, are transcribed from
intergenic and intragenic regions and constitute a broad class of cellular transcripts [10–14]. They play
a critical role in the regulation of gene expression through chromatin remodeling, RNA maturation
(splicing, editing), transport and protein synthesis [15]. Initial evidence suggests that lncRNAs have
essential roles in tumorigenesis [16] and tumor progression [17,18]. Recent studies revealed that
deregulated lncRNAs are found in a number of human cancers [19], including HCC [20–30].
Those aberrantly expressed in HCC tumor compared with non-tumor tissue include HOTAIR (HOX
antisense intergenic RNA), HULC (highly upregulated in liver cancer), MALAT1 (metastasis-associated
lung adenocarcinoma transcript 1), MEG3 (maternally expressed gene 3), MVIH (microvascular invasion
in HCC), and UCA1 (urothelial carcinoma-associated 1) [20–30]. HCC recurrence, metastasis and
prognosis are also predicted by altered lncRNAs including GAS5 (growth arrest-specific transcript 5),
HEIH (high expression in HCC), HOTAIR, HOTTIP (HOXA transcript at the distal tip), MALAT1 and
UCA1 [23,28,30–33]. However, due to their small sample sizes, these prior studies had limited statistical
power to identify reliable lncRNA biomarkers associated with hepatocarcinogenesis and prognosis.
The potential impacts of HCC etiologies (hepatitis B virus (HBV) and hepatitis C virus (HCV) infection)
for lncRNAs expression are also unclear.
Using available paired HCC tumor and adjacent non-tumor tissues collected by the Center for
Liver Disease and Transplantation and the Herbert Irving Comprehensive Cancer Center (HICCC),
Columbia University Medical Center (CUMC), we determined the expression profiles of 90 cancer
related lncRNAs, and explored their potential association with hepatocarcinogenesis, hepatitis virus
infection or HCC survival.
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2. Materials and Methods
2.1. Patients and Tissue Samples
This study was approved by the Institutional Review Board of CUMC. Sixty-six frozen tumor and
paired adjacent non-tumor tissues were obtained from HCC patients who underwent either surgical
resection or liver transplant at CUMC. Histological evaluation was performed in the Molecular Pathology
Shared Resource of the HICCC by the study pathologist (H.R.). Tumor samples were macrodissected
to assess presence and percent of tumor and ensure >80% purity of tumor. Tumor stage was determined
according to the American Joint Committee on Cancer (AJCC) criteria [34]. Separate blocks of
non-tumor liver tissues were evaluated with respect to presence (Batts-Ludwig stage of 4) or absence of
cirrhosis (Batts-Ludwig stage < 4). Information on viral infection (HBV, HCV) and clinicopathological
features including α-fetoprotein levels, tumor size, tumor number, tumor differentiation, vascular
invasion, and capsular infiltration were obtained from the medical records.
2.2. RNA Extraction and lncRNA Measurement
Total RNA was extracted from HCC tumor and adjacent non-tumor tissues by RNeasy Microarray
Tissue Mini Kits (Qiagen, Frederick, MA, USA) according to the manufacturer’s protocol.
RNA quantification and quality were evaluated with an Agilent 2100 Bioanalyzer. The Lnc Profiler™
qPCR Array (System Biosciences (SBI), Mountain View, CA, USA) was used to measure the expression
of 90 lncRNAs that were chosen using the following criteria: (1) LncRNA sequence was well curated
and accepted; (2) in one or more publications lncRNA was implication in human cancer and stem cells;
(3) Primer sets and sequences were available in prior publications; (4) Primer sets passed internal SBI
quality control for specificity performance. Five housekeeping genes (18S rRNA, RNU43, GAPDH,
LAMIN A/C, and U6) and one negative control were used as reference controls to adjust the expression
of candidate lncRNAs (Supplementary Table S1). One sample failed array detection, and was omitted
from final data analysis. Briefly, 1.2 µg isolated RNA (5 µL) was mixed with reagents (PolyA Buffer,
MnCl2, ATP and PolyA Polymerase) to polyadenylate all lncRNAs. Then the oligo dT adaptor and
random primers were added and samples incubated at 42 ˝C for 60 min., and heated at 95 ˝C for 10 min.
to complete cDNA conversion to enhance qPCR assay performance. Finally, the expression profiles for
lncRNAs were determined by SYBR Green based qPCR run in 96-well plates on an Applied Biosystems
7500 Real-time PCR System. The cycle of threshold (Ct) was determined for each lncRNA, and the
raw Ct values were normalized by the geometric mean of the 5 housekeeping genes to indicate lncRNA
expression level. The relative amount of each lncRNA was described as fold-change between tumor and
non-tumor tissues using the equation of 2´∆∆Ct [35]. A representative result of lncRNAs fold-change is
shown in Supplementary Figure S1.
2.3. Statistical Analysis
The expression levels of lncRNAs were displayed as log2 transferred geometric mean. Paired t-test
was used to analyze the expression difference between tumor and adjacent non-tumor tissues.
Two-sample t test was used to determine the expression differences by HBV and HCV status within
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non-tumor tissues. Kaplan-Meier survival analysis and log rank test were used to assess differences
of survival months by aberrant lncRNAs status (categorized by the median in survival cases).
Cox proportional hazard models were conducted to determine the impact of lncRNAs and
clinicopathologic parameters on overall survival (defined as the time between surgical resection or
liver transplant and death from any cause or last follow-up). Age and survival months were treated as
continuous variables, while type of surgery (resection vs. transplant), gender, ethnicity, virus infection
status, cirrhosis, tumor size (ě4 cm vs. < 4 cm), and tumor grade (IV vs. III vs. I–II) were treated
as categorical variables. Logistic regression was used to construct receiver operating characteristic
(ROC) curves for each lncRNA and clinical factor that may potentially predict HCC survival. Finally,
7 lncRNAs (as continuous variables), tumor size and type of surgery (as categorical variables) were
chosen using a stepwise model selection method to construct an optimal model. The maximum
sensitivity, specificity and the area under the curve (AUC) were estimated using 0.5 probability of death
as the cutoff point [36]. All statistical analyses were performed using Statistical Analysis System 9.0
(SAS Institute, Cary, NC, USA).
3. Results
3.1. Clinical and Pathological Characteristics
Table 1 shows the clinical and pathological characteristics of the 65 HCC patients. The average age
of cancer diagnosis is 59.5 years, and over half are older than 60 years (57%). Most patients are male
(75%) and Caucasian (51%). The HBV and HCV infection frequencies are, respectively 20% and 29%,
similar to that of being both virus negative (28%). Among all patients, 72% have pathologically defined
cirrhosis and 60% have grade III or IV tumors.
Table 1. Clinical and pathological characteristics.
Variables No. of Cases (%)
Age at diagnosis (yrs), Mean ˘ SD 59.5 ˘ 14.7
Age group
<60 years 28 (43)
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Table 1. Cont.
Variables No. of Cases (%)
Viral infection
HBV (´), HCV (´) 18 (28)
HBV (´), HCV (+) 19 (29)
HBV (+), HCV (´) 13 (20)




















* Edmondson and Steiner grade.
3.2. Differentially Expressed lncRNAs in HCC Tissues
A total of 90 lncRNAs were measured in the current study, and a Volcano Plot used to show expression
differences between tumor and non-tumor tissues (Supplementary Figure S2). Among them, 55 lncRNAs
expressed in over 90% of samples were analyzed. Eight (lincRNA-VLDLR, MEG9, H19 antisense,
ncR-uPAR, NEAT1 (family), LUST, UM9-5, and HOTAIR) were significantly down-regulated in HCC
tumor compared to non-tumor tissues at a significance level of p < 0.05 (Table 2). The fold changes
ranged from ´2.1 to ´2.8. However, after Bonferroni correction for multiple comparisons, no lncRNA
marker achieved statistical significance with false discovery rates (FDR) ranging from 0.19 to 0.29.
Previously, four lncRNAs (H19, HOTAIR, HULC and MALAT1) were reported to be associated with
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HCC, but only HOTAIR was borderline significance (Table 2) in the current study. These results may be
due to the heterogeneity of HCC tumors with various etiologies.
Table 2. Deregulated lncRNAs expression (Log2 of geometric mean) in HCC tumor
compared with non-tumor tissues (N = 65 pairs).
lncRNAs Tumor Non-Tumor Fold-Change Unadjusted p-Value FDR
lincRNA-VLDLR ´4.6 ´3.4 ´2.4 0.005 0.188
MEG9 ´5.6 ´4.2 ´2.8 0.010 0.188
H19 antisense ´1.3 0.2 ´2.7 0.010 0.188
ncR-uPAR ´1.3 ´0.03 ´2.6 0.018 0.188
NEAT1 (family) ´2.4 ´1.3 ´2.2 0.021 0.188
LUST ´0.5 0.6 ´2.1 0.037 0.287
UM9-5 ´8.7 ´7.6 ´2.5 0.042 0.287
HOTAIR ´8.8 ´7.1 ´2.6 0.048 0.287
3.3. Deregulated lncRNAs in HBV- or HCV-Related HCC
Categorizing tissues by viral status, we separately analyzed the expression patterns of lncRNAs
in HBV or HCV-related HCC. Seven lncRNAs were significantly repressed in HBV positive
tumors compared with paired non-tumor tissues (Table 3). including two markers first identified in
HCC—Kcnq1ot1 (KCNQ1 overlapping transcript 1), a well-characterized tumor suppressor [37] and
NRON [noncoding repressor of NFAT (nuclear factor of activated T-cells)] [38] to repress NFAT
functions involved in carcinogenesis, cancer cell proliferation and metastasis [39,40]. The fold changes
of Kcnq1ot1 and NRON ranged from ´5.3 to ´9.1. Similarly, no significant lncRNA was found
between HBV-positive tumor and adjacent non-tumor tissues after Bonferroni correction for multiple
comparisons. No significant lncRNA distinguished HCV positive tumors (N = 19), or viral negative
tumors (N = 18) from paired non-tumor tissues.
Table 3. Deregulated lncRNAs expression (Log2 of geometric mean) in HBV-related HCC
tumor compared with non-tumor tissues (N = 13 pairs).
lncRNAs Tumor Non-Tumor Fold-Change Unadjusted p-value FDR
Kcnq1ot1 ´8.9 ´5.2 ´9.1 0.005 0.215
TncRNA ´5.5 ´4.0 ´2.9 0.009 0.215
lincRNA-VLDLR ´3.8 ´1.8 ´4.2 0.014 0.215
Zfhx2as ´2.0 0.8 ´6.7 0.019 0.215
NRON ´6.1 ´3.7 ´5.3 0.020 0.215
HOTTIP ´9.8 ´7.8 ´4.2 0.025 0.231
lincRNA-RoR ´9.5 ´7.7 ´3.4 0.046 0.273
We separately compared lncRNAs patterns within tumor and non-tumor tissues by viral status.
No lncRNAs were significantly differentially expressed by viral status within tumor tissue comparisons.
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Only Kcnq1ot1 and NRON were significantly up-regulated in HBV positive compared with viral negative
non-tumor tissues (Table 4). The fold changes were from 5.4 to 12.6. No significant lncRNA was
obtained after adjusting for multiple comparisons.
Table 4. Deregulated lncRNAs (Log2 of geometric mean) significantly associated with HBV










Kcnq1ot1 ´8.9 ´5.2 12.6 0.004 0.193
NRON ´6.2 ´3.7 5.4 0.042 0.947
3.4. Aberrant Expression of lncRNAs in Tumor Tissue and Prediction for HCC Survival
We examined the potential role of aberrantly expressed lncRNAs in tumor tissue and prediction
of HCC survival and mortality. Seven aberrantly expressed lncRNAs were observed including
two up-regulated (Kcnq1ot1, PRINS) and five repressed (21A, SNHG4, BACE1AS (family), UCA1,
Tmevpg1) lncRNAs in HCC cases with poor survival (Supplementary Table S2). The fold changes
ranged from ´4.7 to 3.7. Individual lncRNA can predict a short HCC survival time with hazard
ratios (HR) ranging from 1.7 to 3.0 after adjustment for age and gender (Supplementary Figure S3).
These values are similar to those for large tumor size (HR = 1.8, 95% CI: 0.8–4.1) and treatment
by resection alone (HR = 5.6, 95% CI: 2.1–15.0)—two known clinical predictors of HCC prognosis.
However, only up-regulated Kcnq1ot1 and treatment of resection achieved statistical significance
(p < 0.05). Patients with both larger tumor size and a resection had significantly reduced survival
(HR = 3.6, 95% CI: 1.2–10.5) compared with those having small tumors or liver transplant (Figure 1A).
Carrying more aberrant lncRNA markers (6–7) also showed a borderline significant reduction in survival
(HR = 8.5, 95% CI: 1.0–72.5) compared with carrying fewer (0–3) markers (Figure 1B), indicating the
potential role of a panel of lncRNAs, not individual lncRNA, in prediction of HCC prognosis.
The predictive accuracy depicted by the AUC for individual lncRNA ranged from 0.62 to 0.71
(p < 0.20), similar to that for large tumor size (0.63) and resection treatment (0.64) adjusted for age and
gender (Supplementary Figure S4). A combination of deregulated Kcnq1ot1, 21A, SNHG4, BACE1AS
(family), PRINS, UCA1 and Tmevpg1 significantly predicted (likelihood ratio test p = 0.001) HCC
survival with an AUC of 0.93, 73% sensitivity and 83% specificity (Figure 2A) after adjusting for age and
gender. When including seven lncRNAs (continuous variables), tumor size, type of surgery (categorical
variables) and covariates (age and gender) in a multivariate logistic regression model, we obtained an
optimal HCC survival model with an AUC of 0.96 (87% sensitivity and 87% specificity) (Figure 2B).
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Figure 2. ROC curves of deregulated lncRNAs, tumor size and type of surgery for prediction 
of HCC survival. (A) shows an AUC of 0.93, a sensitivity of 73%, and a specificity of 83% 
for the combination of 7 aberrant lncRNAs in tumor tissue in prediction of HCC survival 
adjusted for age and gender; (B) displays an AUC of 0.96 when combining 7 aberrant 
lncRNAs, tumor size and type of surgery in prediction of HCC survival adjusted for age and 
gender. 
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(Table 2), or associated with HBV-infected HCC (Table 3). However, none achieved statistical 
significance after Bonferroni correction for multiple comparisons indicating the biological role of these 
lncRNAs in hepatocarcinogenesis needs further clarification. 
Four identified lncRNAs have limited data to indicate their biological role in tumorigenesis. lincRNA-
VLDLR (very low density lipoprotein receptor) belongs to the low density lipoprotein receptor family 
that has multiple functions in binding numerous ligands, and regulating cellular signaling. lincRNA-
VLDLR has been detected in HCC tissues and hepatoma cell lines [41], but is repressed in HCC tumor 
tissue in the current study. Three biological mechanisms may be involved in its deregulation: as a direct 
target of miR-135a-5p [42]; hypermethylation of the gene (9p24.2) promoter [43] and homozygous loss 
of the gene observed in genome-wide screening for copy-number alterations in cancer cell lines, albeit 
infrequently [43]. LUST (LUCA-15-Specific Transcript) is mapped to the antisense strand of gene RBM5 
(3p21.3) that functions as a putative tumor suppressor [44]. Ectopic overexpression of LUST coincides 
with elevated expression of full-length RBM5, and reduced expression of the truncated, cytotoxic RBM5, 
which inhibits cellular proliferation and enhances apoptosis [45]. The KCNQ1 cluster (11p15) contains 
approximately 10 paternally imprinted genes, whose expression is regulated by a tumor suppressor 
Kcnq1ot1 [37], also known as LIT1. Loss of expression of Kcnq1ot1 in colorectal cancer [46] and 
repression in skin cancer [47] is mainly controlled by epigenetic modifications, i.e., aberrant DNA 
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4. Discussion
We examined 90 lncRNAs in 65 HCC tissues, and identified a panel of lncRNAs repressed in
HCC (Table 2), or associated with HBV-infected HCC (Table 3). However, none achieved statistical
significance after Bonferroni correction for multiple comparisons indicating the biological role of these
lncRNAs in hepatocarcinogenesis needs further clarification.
Four identified lncRNAs have limited data to indicate their biological role in tumorigenesis.
lincRNA-VLDLR (very low density lipoprotein receptor) belongs to the low density lipoprotein receptor
family that has multiple functions in binding numerous ligands, and regulating cellular signaling.
lincRNA-VLDLR has been detected in HCC tissues and hepatoma cell lines [41], but is repressed in HCC
tumor tissue in the current study. Three biological mechanisms may be involved in its deregulation: as a
direct target of miR-135a-5p [42]; hypermethylation of the gene (9p24.2) promoter [43] and homozygous
loss of the gene observed in genome-wide screening for copy-number alterations in cancer cell lines,
albeit infrequently [43]. LUST (LUCA-15-Specific Transcript) is mapped to the antisense strand of
gene RBM5 (3p21.3) that functions as a putative tumor suppressor [44]. Ectopic overexpression of
LUST coincides with elevated expression of full-length RBM5, and reduced expression of the truncated,
cytotoxic RBM5, which inhibits cellular proliferation and enhances apoptosis [45]. The KCNQ1 cluster
(11p15) contains approximately 10 paternally imprinted genes, whose expression is regulated by a tumor
suppressor Kcnq1ot1 [37], also known as LIT1. Loss of expression of Kcnq1ot1 in colorectal cancer [46]
and repression in skin cancer [47] is mainly controlled by epigenetic modifications, i.e., aberrant DNA
methylation, interaction with DNA (cytosine-5-)-methyltransferase 1 (DNMT1), enrichment of H3 lysine
9 dimethylation (H3K9me2) and reduction of H3 lysine 4 (H3K4) demethylation [46–48]. A novel short
tandem repeat (STR) polymorphism in Kcnq1ot1 was significantly associated with higher expression of
Kcnq1ot1 (21–33 folds) and decreased risk of HCC (OR = 0.38, 95% CI: 0.21–0.69) [49]. Although no
direct evidence to indicate the anti-cancer role of NRON, its repression for NFAT that plays pivotal role
in tumorigenesis, cell proliferation, migratory, invasive and drug resistance, suggests a potential tumor
suppressive function [39,40]. However, previous studies are not always consistent. The activation of
estrogen signaling in breast cancer cells appeared to enhance expression of Kcnq1ot1 and repression of
CDKN1C (cyclin-dependent kinase inhibitor 1C) that is concomitant with loss of Kcnq1ot1 methylation
in its promoter CpG island [50]. Similar inverse correlations betweenKcnq1ot1 andCDKN1C expression
were observed in three hepatoma cell lines [49], indicating a diverse and complex bidirectional regulatory
role for lncRNAs in tumorigenesis. This is consistent with our discrepant observations that repressed
Kcnq1ot1 and NRON were observed in HBV-related HCC tumor compared with adjacent non-tumor
tissues (Table 3), while up-regulated Kcnq1ot1 and NRON were found in HBV-related HCC compared
with viral negative non-tumor tissues (Table 4). One explanation is that, when HBV infects liver tissue,
the expression of Kcnq1ot1 (as a tumor suppressor) is activated in order to preclude the carcinogenic
effect of HBV infection, or try to compensate for its partially disrupted tumor suppressive function.
A similar mechanism may be also applied to NRON regulation, which is supported by a recent
finding that NRON expression can modulate HIV-1 replication, and knockdown of NRON enhances
the replication of HIV-1 through increased activity of NFAT [51]. It is biologically plausible given
the features of lncRNAs that regulate protein-coding gene expression at both post-transcriptional and
transcriptional levels [52]. For transcriptional regulation, lncRNAs can recruit chromatin-modifying
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enzymes to positively or negatively control a protein-coding gene’s expression, either in cis (near the
site of lncRNA) or in trans (the involved genes are distant) [53]. Other potential mechanisms involved
in these discrepant effects of deregulated lncRNAs need further exploration in hepatocarcinogenesis.
We found that seven lncRNAs in tumor tissues has pronounced predictive capability for HCC survival
(HRs from 1.7 to 3.0), but only one achieves statistically significant level (Supplementary Figure S3).
Carrying 6–7 aberrantly expressed lncRNAs was associated with a borderline significant reduction in
survival (HR = 8.5, 95% CI: 1.0–72.5) compared with carrying fewer aberrant markers (Figure 1).
This data suggests that a panel of deregulated lncRNAs may serve as a marker to predict HCC survival.
Several previous studies have observed that a few different lncRNAs are independent predictors of HCC
prognosis [23,28,30–33]. Studies in liver transplant patients found that overexpression of HOTAIR
and MALAT1 were independent predictors for HCC recurrence. The HRs were, respectively 3.6 (95%
CI: 1.7–7.6) and 3.3 (95% CI: 1.5–7.1) [23,28]. Overexpressed HOTTIP was significantly associated
with increased metastasis and decreased overall survival for HCC patients with mixed etiologies [31].
A high level of HEIH has been found significantly associated with HBV-related HCC recurrence (HR =
2.1; 95% CI: 1.2–3.7) [33], while another study found HCC patients with lower levels of GAS5 in tumor
tissue had a worse overall survival than patients with higher expression (HR = 2.4; 95% CI: 1.6–4.1) [32].
Upregulated UCA1 was significantly correlated with advanced HCC TNM stage, metastasis and poor
5-year survival [30]. However, these studies did not adjust for patients’ demographic characteristics
(age, gender) and clinical pathological factors (tumor size, stage, grade, and treatment status) that are
associated with HCC survival. It is unable to completely exclude the potential bias of those factors on
lncRNAs expression and HCC survival.
Most studies using individual lncRNAs as a predictor for cancer survival had much poorer accuracy
than those using a panel of lncRNAs. For the first time, we used a panel of seven deregulated
lncRNAs to obtain a predictive accuracy (AUC) of 0.93 (Figure 2) in prediction of HCC survival,
which is similar to the AUC (0.96) when combing the seven lncRNAs with tumor size and type of
surgery (sensitivity = 87%, specificity = 87%). Except for UCA1, the other lncRNAs (Kcnq1ot1, 21A,
SNHG4, BACE1AS (family), PRINS and Tmevpg1) identified in this panel have not been previously
reported to be associated with HCC survival. Accumulating evidence from survival studies in other
tumors and the analysis of relevant biological pathways or genes support their potential role in
prediction of HCC prognosis. Upregulated UCA1 in HCC can promote progression through a novel
UCA1-miR-216b-FGFR1-ERK signaling pathway [30]. UCA1 has also been found to enhance bladder
cancer cell proliferation and metastasis by disrupting the PI3K/Wnt signaling pathway [54,55]. A low
expression level of PRINS (psoriasis susceptibility-related RNA gene induced by stress) was found
to be associated with adrenocortical carcinoma (ACC) recurrence and distant metastatic disease [56]
because of its regulation of G1P3, an anti-apoptotic gene [57]. Aberrant expression of UCA1 (urothelial
carcinoma-associated 1) and three other lncRNAs were found in the co-expression network with
26 mRNAs involved in the progression of gastric cancer [58]. BACE1AS (antisense transcript for
β-secretase-1) was downregulated in 5-fluorouracil (5-FU) resistant cells derived from the human colon
cancer [59] that may impact the efficacy of treatment and lead to poor prognosis. However, these data
are far from sufficient to clearly characterize the functional lncRNAs involved in HCC progression.
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Several previous studies have identified panels of deregulated lncRNAs in association with HCC
tumors, hepatitis infection, as well as survival, but the results vary greatly. These differences may
be due to the heterogeneity of liver tissues with various HCC etiologies (age and gender, HBV, HCV,
alcoholic or steatohepatitis) and pathological characteristics (tumor size, stage, cirrhosis, inflammation
activities, treatment status, etc.). Use of different molecular techniques to measure lncRNAs or selection
of different samples (adjacent non-tumor tissue, cirrhotic tissue or normal liver tissues) as comparison
tissues may also lead to inconsistent results. The types and numbers of endogenous controls used to
normalize lncRNAs expression levels vary by study and may also cause the discrepancy. Therefore,
well-designed studies are needed to better elucidate liver specific lncRNA alterations associated with
hepatocarcinogenesis, viral etiologies or HCC prognosis.
One limitation of the current study is lack of gene expression profiles that enable construction of
lncRNA-mRNA co-expression networks to further understand relevant biological functions of interesting
lncRNAs. When categorized by HCC etiologies or survival status, the subgroups’ sample sizes are small.
Although several panels of lncRNAs were aberrantly expressed in either overall HCC or HBV-related
HCC or poor survival HCC, no lncRNA achieved statistical significance after Bonferroni correction for
multiple comparisons. Therefore, our findings should be interpreted with caution. Further large studies
using homogenous HCC etiologies are needed to draw firm conclusions.
5. Conclusions
We identified a panel of eight lncRNAs associated with HCC occurrence, seven lncRNAs repressed
in HBV-related HCC, and seven lncRNAs aberrantly expressed in HCC patients with poor survival.
A combination of the seven lncRNAs and large tumor size and resection treatment can accurately predict
HCC survival with an AUC of 0.96 and a sensitivity/specificity of 87%. These data suggest that a panel
of lncRNAs may serve as potential markers for HCC early diagnosis and prediction of survival. However,
large studies are needed to validate these findings due to the limitations mention above.
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